QID 240774

Date Published: 2022-10-26

QID 240774: Red Hat Update for java-1.8.0-ibm (RHSA-2022:6735)

Ibm java se version 8 includes the ibm java runtime environment and the ibm java software development kit...Security Fix(es):

    openjdk: incomplete enforcement of jar signing disabled algorithms (libraries, 8249906) (cve-2021-2163).
Affected Products:
    Red Hat enterprise linux for x86_64 8 x86_64.
    Red hat enterprise linux for x86_64 - extended update support 8.6 x86_64.
    Red hat enterprise linux for ibm z systems 8 s390x.
    Red hat enterprise linux for ibm z systems - extended update support 8.6 s390x.
    Red hat enterprise linux for power, little endian 8 ppc64le.
    Red hat enterprise linux for power, little endian - extended update support 8.6 ppc64le.
.

Note: The preceding description block is extracted directly from the security advisory. Using automation, we have attempted to clean and format it as much as possible without introducing additional issues.

Successful exploitation of this vulnerability could lead to a security breach or could affect integrity, availability, and confidentiality.

  • CVSS V3 rated as Medium - 5.3 severity.
  • CVSS V2 rated as Low - 2.6 severity.
    • Solution
    Refer to Red Hat security advisory RHSA-2022:6735 for updates and patch information.
    Vendor References

    CVEs related to QID 240774

    CVE-2021-2163 |
    Software Advisories
    Advisory ID Software Component Link
    RHSA-2022:6735 Red Hat Enterprise Linux URL Logo access.redhat.com/errata/RHSA-2022:6735
    By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].